NCT01534403 - Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions

Systemic Lupus Erythematosus

Interventions

BIOLOGICAL

Epratuzumab

Epratuzumab 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles (ie, Weeks 0, 1, 2, 3, 12, 13, 14, 15, 24, 25, 26, 27, 36, 37, 38, 39, 48, 49, 50, 51, 60, 61, 62, 63, 72, 73, 74, 75, 84, 85, 86, and 87)

Trial Locations (6)

Unknown

10, Fukuoka

11, Fukuoka

9, Fukuoka

3, Kitakyushu

1, Tokyo

8, Tokyo